|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NCS1 |
Gene summary for NCS1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NCS1 | Gene ID | 23413 |
| Gene name | neuronal calcium sensor 1 | |
| Gene Alias | FLUP | |
| Cytomap | 9q34.11 | |
| Gene Type | protein-coding | GO ID | GO:0001505 | UniProtAcc | P62166 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23413 | NCS1 | LZE7T | Human | Esophagus | ESCC | 1.34e-02 | 1.60e-01 | 0.0667 |
| 23413 | NCS1 | LZE6T | Human | Esophagus | ESCC | 8.48e-04 | 1.37e-01 | 0.0845 |
| 23413 | NCS1 | P4T-E | Human | Esophagus | ESCC | 1.47e-07 | 8.76e-02 | 0.1323 |
| 23413 | NCS1 | P8T-E | Human | Esophagus | ESCC | 3.40e-05 | 1.89e-01 | 0.0889 |
| 23413 | NCS1 | P9T-E | Human | Esophagus | ESCC | 3.68e-05 | 6.62e-02 | 0.1131 |
| 23413 | NCS1 | P10T-E | Human | Esophagus | ESCC | 2.11e-06 | 2.05e-01 | 0.116 |
| 23413 | NCS1 | P11T-E | Human | Esophagus | ESCC | 2.13e-03 | 2.31e-01 | 0.1426 |
| 23413 | NCS1 | P15T-E | Human | Esophagus | ESCC | 1.38e-04 | 1.90e-01 | 0.1149 |
| 23413 | NCS1 | P17T-E | Human | Esophagus | ESCC | 4.28e-06 | 2.34e-01 | 0.1278 |
| 23413 | NCS1 | P19T-E | Human | Esophagus | ESCC | 2.59e-03 | 2.15e-01 | 0.1662 |
| 23413 | NCS1 | P21T-E | Human | Esophagus | ESCC | 2.60e-18 | 4.29e-01 | 0.1617 |
| 23413 | NCS1 | P28T-E | Human | Esophagus | ESCC | 5.85e-04 | 8.92e-02 | 0.1149 |
| 23413 | NCS1 | P30T-E | Human | Esophagus | ESCC | 1.45e-07 | 4.03e-01 | 0.137 |
| 23413 | NCS1 | P31T-E | Human | Esophagus | ESCC | 1.10e-14 | 3.19e-01 | 0.1251 |
| 23413 | NCS1 | P32T-E | Human | Esophagus | ESCC | 7.55e-13 | 2.69e-01 | 0.1666 |
| 23413 | NCS1 | P37T-E | Human | Esophagus | ESCC | 5.37e-10 | 2.54e-01 | 0.1371 |
| 23413 | NCS1 | P40T-E | Human | Esophagus | ESCC | 7.65e-03 | 7.53e-02 | 0.109 |
| 23413 | NCS1 | P42T-E | Human | Esophagus | ESCC | 4.94e-03 | 8.28e-02 | 0.1175 |
| 23413 | NCS1 | P48T-E | Human | Esophagus | ESCC | 6.07e-03 | 7.81e-02 | 0.0959 |
| 23413 | NCS1 | P52T-E | Human | Esophagus | ESCC | 6.25e-09 | 2.05e-01 | 0.1555 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001097516 | Esophagus | ESCC | regulation of neuron projection development | 240/8552 | 445/18723 | 2.48e-04 | 1.53e-03 | 240 |
| GO:001097510 | Oral cavity | OSCC | regulation of neuron projection development | 210/7305 | 445/18723 | 2.35e-04 | 1.52e-03 | 210 |
| GO:001097521 | Oral cavity | NEOLP | regulation of neuron projection development | 77/2005 | 445/18723 | 1.44e-05 | 2.53e-04 | 77 |
| GO:001097517 | Skin | AK | regulation of neuron projection development | 79/1910 | 445/18723 | 6.49e-07 | 2.23e-05 | 79 |
| GO:001097522 | Skin | cSCC | regulation of neuron projection development | 141/4864 | 445/18723 | 3.72e-03 | 1.99e-02 | 141 |
| GO:0010975110 | Thyroid | PTC | regulation of neuron projection development | 194/5968 | 445/18723 | 1.05e-07 | 2.08e-06 | 194 |
| GO:001097523 | Thyroid | ATC | regulation of neuron projection development | 212/6293 | 445/18723 | 4.16e-10 | 1.14e-08 | 212 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NCS1 | SNV | Missense_Mutation | c.284N>A | p.Gly95Glu | p.G95E | P62166 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-C8-A275-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| NCS1 | SNV | Missense_Mutation | c.246C>A | p.Phe82Leu | p.F82L | P62166 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| NCS1 | SNV | Missense_Mutation | rs781937299 | c.263C>T | p.Ala88Val | p.A88V | P62166 | protein_coding | deleterious(0.03) | probably_damaging(0.99) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| NCS1 | SNV | Missense_Mutation | rs200938140 | c.236N>A | p.Arg79Gln | p.R79Q | P62166 | protein_coding | tolerated(0.26) | benign(0.015) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| NCS1 | SNV | Missense_Mutation | novel | c.500N>G | p.Gln167Arg | p.Q167R | P62166 | protein_coding | deleterious(0.04) | benign(0.081) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| NCS1 | SNV | Missense_Mutation | c.196N>G | p.Thr66Ala | p.T66A | P62166 | protein_coding | tolerated(0.28) | benign(0) | TCGA-AZ-4615-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | xeloda | PD | |
| NCS1 | SNV | Missense_Mutation | c.246N>A | p.Phe82Leu | p.F82L | P62166 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD | |
| NCS1 | SNV | Missense_Mutation | c.331N>T | p.Asp111Tyr | p.D111Y | P62166 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| NCS1 | SNV | Missense_Mutation | rs370911031 | c.305N>A | p.Arg102Gln | p.R102Q | P62166 | protein_coding | tolerated(0.45) | benign(0.001) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NCS1 | SNV | Missense_Mutation | rs781937299 | c.263N>T | p.Ala88Val | p.A88V | P62166 | protein_coding | deleterious(0.03) | probably_damaging(0.99) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |